Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations

Tarek Daoud(The University of Texas MD Anderson Cancer Center), Lilie L. Lin(The University of Texas MD Anderson Cancer Center), Jiansong Chen(The University of Texas MD Anderson Cancer Center), Peng Wei(Creighton University), Franklin C. Wong(The University of Texas MD Anderson Cancer Center), Timothy A. Yap(The University of Texas MD Anderson Cancer Center)
European Journal of Nuclear Medicine and Molecular Imaging
November 18, 2025
10.1007/s00259-025-07595-3
Cited by 1

Related Papers

Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
|Nature Medicine|2023|372
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
|Cancer Cell|2019|243
Gut commensal <i>Parabacteroides distasonis</i> alleviates inflammatory arthritis
|Gut|2023|237